Michael S. Ominsky

10.3k total citations · 2 hit papers
88 papers, 6.3k citations indexed

About

Michael S. Ominsky is a scholar working on Orthopedics and Sports Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Michael S. Ominsky has authored 88 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Orthopedics and Sports Medicine, 61 papers in Molecular Biology and 45 papers in Oncology. Recurrent topics in Michael S. Ominsky's work include Bone health and osteoporosis research (61 papers), Bone Metabolism and Diseases (55 papers) and Bone health and treatments (42 papers). Michael S. Ominsky is often cited by papers focused on Bone health and osteoporosis research (61 papers), Bone Metabolism and Diseases (55 papers) and Bone health and treatments (42 papers). Michael S. Ominsky collaborates with scholars based in United States, Canada and Switzerland. Michael S. Ominsky's co-authors include Hua Zhu Ke, Xiaodong Li, Paul J. Kostenuik, William G. Richards, Marina Stolina, Denise Dwyer, Qing‐Tian Niu, Frank Asuncion, W. Scott Simonet and Rogely Boyce and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Michael S. Ominsky

82 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dickkopf-1 is a master regulator of joint remodeling

2007 1.0k citations Marina Stolina, Michael S. Ominsky et al. profile →
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

2008 613 citations Xiaodong Li, Michael S. Ominsky et al. Journal of Bone and Mineral Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael S. Ominsky United States	41	3.9k	2.9k	2.8k	1.1k	992	88	6.3k
Joseph Lorenzo United States	43	4.2k 1.1×	1.2k 0.4×	2.7k 1.0×	799 0.7×	581 0.6×	85	6.4k
Gary Hattersley United States	31	2.3k 0.6×	2.0k 0.7×	1.9k 0.7×	323 0.3×	465 0.5×	65	4.1k
Hong‐Lin Tan United States	12	3.9k 1.0×	1.2k 0.4×	2.9k 1.0×	803 0.7×	415 0.4×	15	5.3k
Kazuki Yano Japan	18	6.2k 1.6×	1.8k 0.6×	4.6k 1.7×	1.2k 1.1×	378 0.4×	26	7.7k
N. Nakagawa Japan	12	6.6k 1.7×	1.8k 0.6×	4.9k 1.7×	1.3k 1.2×	371 0.4×	21	8.2k
Tatsuo Suda Japan	13	3.4k 0.9×	870 0.3×	2.5k 0.9×	698 0.6×	326 0.3×	14	4.5k
J.N. Beresford United Kingdom	28	2.0k 0.5×	595 0.2×	972 0.3×	882 0.8×	413 0.4×	51	4.4k
Saeid M. Seyedin United States	30	2.7k 0.7×	594 0.2×	1.1k 0.4×	830 0.7×	475 0.5×	42	4.3k
Su‐Li Cheng United States	32	2.4k 0.6×	351 0.1×	682 0.2×	635 0.6×	732 0.7×	53	4.4k
Leonard Rifas United States	27	1.7k 0.4×	562 0.2×	941 0.3×	630 0.5×	480 0.5×	49	3.5k

Countries citing papers authored by Michael S. Ominsky

Since Specialization

Citations

This map shows the geographic impact of Michael S. Ominsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Ominsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Ominsky more than expected).

Fields of papers citing papers by Michael S. Ominsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Ominsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Ominsky. The network helps show where Michael S. Ominsky may publish in the future.

Co-authorship network of co-authors of Michael S. Ominsky

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Ominsky. A scholar is included among the top collaborators of Michael S. Ominsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Ominsky. Michael S. Ominsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Xiaodong, Frank Asuncion, Michael S. Ominsky, et al.. (2025). High-dose romosozumab promoted bone regeneration of critical-size ulnar defect filled with demineralized bone matrix in nonhuman primates. Journal of Orthopaedic Translation. 54. 1–7.

Glorieux, Francis H., Bente Langdahl, Roland Chapurlat, et al.. (2024). Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. Journal of Bone and Mineral Research. 39(9). 1215–1228. 9 indexed citations

Tsourdi, Elena, Aliya Khan, Mishaela R. Rubin, et al.. (2024). Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial. Osteologie/Osteology. 33(2). 113–113. 1 indexed citations

Florio, Mónica, Paul J. Kostenuik, Marina Stolina, et al.. (2023). Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone. Journal of Bone and Joint Surgery. 105(15). 1145–1155. 7 indexed citations

Winzenrieth, Renaud, Michael S. Ominsky, Yamei Wang, Ludovic Humbert, & R. J. Weiss. (2021). Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporosis International. 32(3). 575–583. 29 indexed citations

Lanske, Beate, Heidi Chandler, Allen R. Pierce, et al.. (2019). Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture. Journal of Orthopaedic Research®. 37(4). 812–820. 19 indexed citations

Ominsky, Michael S., Jean‐Pierre Devogelaer, Daniel Chappard, et al.. (2019). Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone. 124. 137–147. 35 indexed citations

Taylor, Scott L., Efrain Pacheco, Kathrin Locher, et al.. (2018). Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats. Bone Reports. 8. 95–103. 17 indexed citations

Chandler, Heidi, Beate Lanske, Aurore Varela, et al.. (2018). Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 120. 148–155. 29 indexed citations

10.

Ominsky, Michael S., et al.. (2017). Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys. Calcified Tissue International. 101(1). 82–91. 8 indexed citations

11.

Jolette, Jacquelin, Aurore Varela, Gerald G. Long, et al.. (2017). Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1–34). Regulatory Toxicology and Pharmacology. 86. 356–365. 68 indexed citations

12.

Bonnet, Nicolas, Maude Gerbaix, Michael S. Ominsky, et al.. (2016). Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice. Calcified Tissue International. 99(1). 99–109. 5 indexed citations

13.

Taylor, Scott L., Michael S. Ominsky, Rong Hu, et al.. (2015). Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone. 84. 148–159. 77 indexed citations

14.

Kostenuik, Paul J., Susan Y. Smith, Rana Samadfam, et al.. (2014). Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys. Journal of Bone and Mineral Research. 30(4). 657–669. 35 indexed citations

15.

Li, Xiaodong, Michael S. Ominsky, Kelly Warmington, et al.. (2011). Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats. Endocrinology. 152(9). 3312–3322. 71 indexed citations

16.

Li, Xiaodong, Michael S. Ominsky, Kelly Warmington, et al.. (2008). Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research. 24(4). 578–588. 613 indexed citations breakdown →

17.

Gerstenfeld, Louis C., Zachary Mason, Dana T. Graves, et al.. (2008). Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing. Journal of Bone and Mineral Research. 24(2). 196–208. 181 indexed citations

18.

Lloyd, Shane, Paul J. Kostenuik, Michael S. Ominsky, et al.. (2008). Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice. Calcified Tissue International. 82(5). 361–372. 61 indexed citations

19.

Stolina, Marina, Denise Dwyer, Michael S. Ominsky, et al.. (2007). Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses. The Journal of Immunology. 179(11). 7497–7505. 53 indexed citations

20.

Kostenuik, Paul J., Michael S. Ominsky, Sean Morony, et al.. (2007). Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporosis International. 19(5). 625–635. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact